BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
pharmaphorum2 天
Moderna and BioNTech – who are they?
The rest is history – Pfizer stepped in and licensed the technology, choosing the most promising of four potential mRNA vaccines from BioNTech. Both Moderna and Pfizer’s shots aced the quickly ...
mRNA Cancer Vaccines Clinical Trials Ongoing Research Development Insight
First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick ResearchDelhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Global mRNA Cancer Vaccines Clinical Trials and Market Future Outlook 2024 Report ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after ...
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Nasdaq11 天
BioNTech Initiates Global Clinical Trials for BNT327/PM8002 Combinations and Advances mRNA ...
BioNTech SE is advancing its oncology ... with investigational combination therapies in two pan-tumor technology pillars: our mRNA-based cancer immunotherapies for the early, adjuvant setting ...
The Pharma Letter11 天
BioNTech reveals priorities and progress at JPM
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...
Taiwan News11 天
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ...
“We aim to develop BioNTech into a global immunotherapy powerhouse with the potential to ... In oncology, we are focused on addressing the full spectrum of solid tumors with investigational ...